Fish Oil and Omega-3 for Depression: EPA, BDNF and the Meta-Analysis Evidence

Omega-3 fatty acids have accumulated one of the strongest evidence bases of any nutritional supplement for depression — with a 2019 meta-analysis of 26 RCTs confirming significant antidepressant effects. A critical nuance distinguishes the depression evidence from other omega-3 applications: it is EPA (eicosapentaenoic acid) specifically, not DHA, that drives the antidepressant effect. Understanding this distinction is essential for selecting the right fish oil formulation for mood support rather than simply any omega-3 product.

EPA vs DHA: The Critical Distinction for Depression

Most fish oil supplements contain EPA and DHA in roughly equal ratios. For depression specifically, this matters because:

• EPA is the primary antidepressant omega-3: Multiple meta-analyses have found that the antidepressant effect of omega-3 supplementation is driven by EPA content — supplements with EPA:DHA ratios above 1.5:1 consistently show significant antidepressant effects while pure DHA supplements do not
• DHA alone shows weak antidepressant activity: The largest meta-analyses find DHA-dominant preparations produce non-significant effects on depression scores
• The mechanism difference: EPA produces the anti-inflammatory eicosanoids and resolvins most relevant to the neuroinflammation driving depression; DHA primarily contributes to structural membrane composition with less direct anti-inflammatory signalling

For mood support, choose fish oil with EPA:DHA ratio of at least 2:1, or pure EPA supplements (ethyl-EPA preparations like those used in clinical trials).

Mechanism 1: Neuroinflammation — The Inflammatory Theory of Depression

The inflammatory theory of depression posits that chronic systemic and neurological inflammation drives depressive symptoms through multiple pathways: elevated IL-6, TNF-alpha, and CRP activate the IDO enzyme that diverts tryptophan away from serotonin synthesis toward neurotoxic kynurenine metabolites; neuroinflammation reduces BDNF expression; and inflammatory cytokines directly impair synaptic plasticity in the prefrontal cortex and hippocampus. EPA addresses neuroinflammation through its conversion to resolvins and its competitive inhibition of arachidonic acid-derived pro-inflammatory prostaglandins — directly targeting the biological substrate of inflammation-driven depression.

Mechanism 2: BDNF Upregulation

BDNF (brain-derived neurotrophic factor) is reduced in major depressive disorder — its restoration is increasingly considered a shared mechanism of effective antidepressants including SSRIs, exercise, and omega-3 supplementation. EPA and DHA support hippocampal BDNF expression through their incorporation into neuronal membranes (improving synaptic receptor function) and through resolvin-mediated reduction of the neuroinflammation that suppresses BDNF gene expression. A human study found omega-3 supplementation significantly increased plasma BDNF in depressed patients — correlating with clinical improvement.

Mechanism 3: Serotonin Pathway Support

EPA supports serotonin signalling through two mechanisms: reducing neuroinflammation that activates IDO (preserving tryptophan availability for serotonin synthesis), and directly increasing serotonin release from serotonergic neurons through effects on membrane fluidity and receptor sensitivity. A study found EPA supplementation significantly increased cerebrospinal fluid serotonin metabolites in depressed patients — providing direct neurochemical evidence of serotonergic enhancement.

Research: Meta-Analysis of 26 RCTs

A comprehensive meta-analysis (Liao et al., 2019) of 26 RCTs in 2,160 patients with major depressive disorder found omega-3 supplementation produced significant antidepressant effects (SMD -0.36, 95% CI -0.49 to -0.24). Subgroup analysis confirmed the EPA-specific finding: supplements with ≥60% EPA produced the largest effects. The effect size is clinically meaningful — comparable to some antidepressant medications in mild-to-moderate depression populations.

Research: Adjunct to Antidepressants

Multiple RCTs have specifically examined EPA supplementation added to ongoing SSRI treatment in partial responders. A landmark study (Nemets et al., 2002) found adding EPA (2g daily) to existing antidepressant treatment produced significant additional improvement within 3 weeks compared to placebo addition. A meta-analysis of these adjunct trials found omega-3 augmentation significantly improved response rates in SSRI partial responders — suggesting EPA and SSRIs may work through complementary mechanisms with additive effects.

Dosage for Depression

• Dose: 1-2g EPA daily — as a standalone intervention or adjunct. Most clinical trials used 1-2g pure EPA or EPA-dominant formula
• Form: EPA:DHA ratio ≥2:1 preferred — some trials used pure ethyl-EPA (Eicosapen, Omacor)
• Onset: 4-8 weeks for meaningful antidepressant effects — consistent with the time required for EPA to incorporate into brain cell membranes
• With meals: Fat-containing meal significantly improves omega-3 absorption
• Note: Omega-3 supplements for depression should complement, not replace, professional mental health assessment and treatment